Publications
Detailed Information
The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dae-Hee | - |
dc.contributor.author | Kim, Yong-Jin | - |
dc.contributor.author | Chang, Sung-A | - |
dc.contributor.author | Lee, Hye-Won | - |
dc.contributor.author | Kim, Hyung-Kwan | - |
dc.contributor.author | Sohn, Dae-Won | - |
dc.contributor.author | Park, Young-Bae | - |
dc.contributor.author | Chang, Hyuk-Jae | - |
dc.contributor.author | Kim, Ha-Na | - |
dc.date.accessioned | 2012-06-27T06:02:11Z | - |
dc.date.available | 2012-06-27T06:02:11Z | - |
dc.date.issued | 2010-10 | - |
dc.identifier.citation | EUROPEAN JOURNAL OF HEART FAILURE; Vol.12 10; 1051-1060 | ko_KR |
dc.identifier.issn | 1388-9842 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77592 | - |
dc.description.abstract | To evaluate the protective effect of thalidomide, a potent anti-inflammatory drug, on the development of diabetic cardiomyopathy (DMCMP). We induced type 1 diabetes using streptozocin in 8-week-old Sprague-Dawley rats, divided them into two groups-a thalidomide treatment group (DM-T, n = 15) and a non-treatment group (DM-N, n = 15)-and compared them with a normal control (n = 10). Ten weeks after diabetes induction, heart and lung mass indices were higher in the DM-N group compared with the control group. In the DM-T group, increases in heart and lung mass indices were attenuated compared with the DM-N group. On echocardiographic examination, systolic and diastolic mitral annulus velocities were impaired in the DM-N group, but they remained normal in the DM-T group. On haemodynamic analyses, left ventricular (LV) systolic function, represented by end-systolic elastance (0.35 +/- 0.14 vs. 0.18 +/- 0.07 mmHg/mu l, P < 0.001) and preload-recruitable stroke work (90.5 +/- 24.3 vs. 51.8 +/- 22.0 mmHg, P < 0.001), was preserved in the DM-T group compared with the DM-N group. Likewise, deterioration of LV diastolic function was attenuated in the DM-T group. Increases in serum levels of TNF-alpha were attenuated in the DM-T group compared with the DM-N group. On histological analysis, thalidomide treatment lowered total myocardial collagen content and the expression of TNF-alpha, IL-1 beta, ICAM-1, and VCAM-1. In an animal model of DMCMP, deterioration of LV systolic and diastolic function was partially prevented by thalidomide treatment. | ko_KR |
dc.description.sponsorship | This study was supported by the Korea Research Foundation Grant
funded by the Korean Government (KRF-2007-313-E00217). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | OXFORD UNIV PRESS | ko_KR |
dc.subject | Diabetic cardiomyopathy | ko_KR |
dc.subject | Thalidomide | ko_KR |
dc.subject | Ventricular function | ko_KR |
dc.subject | Streptozocin | ko_KR |
dc.title | The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김대희 | - |
dc.contributor.AlternativeAuthor | 김용진 | - |
dc.contributor.AlternativeAuthor | 장성아 | - |
dc.contributor.AlternativeAuthor | 이효원 | - |
dc.contributor.AlternativeAuthor | 김하나 | - |
dc.contributor.AlternativeAuthor | 김형관 | - |
dc.contributor.AlternativeAuthor | 장혁재 | - |
dc.contributor.AlternativeAuthor | 손대원 | - |
dc.contributor.AlternativeAuthor | 박영배 | - |
dc.identifier.doi | 10.1093/eurjhf/hfq103 | - |
dc.citation.journaltitle | EUROPEAN JOURNAL OF HEART FAILURE | - |
dc.description.citedreference | PEREZ AV, 2009, INT J CARDIOL | - |
dc.description.citedreference | Dunlay SM, 2008, CIRCULATION, V118, P625, DOI 10.1161/CIRCULATIONAHA.107.759191 | - |
dc.description.citedreference | Pacher P, 2008, NAT PROTOC, V3, P1422, DOI 10.1038/nprot.2008.138 | - |
dc.description.citedreference | Westermann D, 2007, DIABETES, V56, P1834, DOI 10.2337/db06-1662 | - |
dc.description.citedreference | Boudina S, 2007, CIRCULATION, V115, P3213, DOI 10.1161/CIRCULATIONAHA.106.679597 | - |
dc.description.citedreference | Loh HK, 2007, BASIC CLIN PHARMACOL, V100, P233 | - |
dc.description.citedreference | Sun M, 2007, CIRCULATION, V115, P1398, DOI 10.1161/CIRCULATIONAHA.106.643585 | - |
dc.description.citedreference | Westermann D, 2007, DIABETES, V56, P641, DOI 10.2337/db06-1163 | - |
dc.description.citedreference | Yndestad A, 2006, EUR J HEART FAIL, V8, P790, DOI 10.1016/j.ejheart.2006.02.007 | - |
dc.description.citedreference | Westermann D, 2006, DIABETOLOGIA, V49, P2507, DOI 10.1007/s00125-006-0385-2 | - |
dc.description.citedreference | Arroba AI, 2006, J ENDOCRINOL, V191, P55, DOI 10.1677/joe.1.06908 | - |
dc.description.citedreference | Leichman JG, 2006, AM J CLIN NUTR, V84, P336 | - |
dc.description.citedreference | Chong LW, 2006, J BIOMED SCI, V13, P403, DOI 10.1007/s11373-006-9079-5 | - |
dc.description.citedreference | Sjoholm A, 2006, DIABETES-METAB RES, V22, P4, DOI 10.1002/dmrr.568 | - |
dc.description.citedreference | Lv P, 2006, MEDIAT INFLAMM, DOI 10.1155/MI/2006/93253 | - |
dc.description.citedreference | Gullestad L, 2005, CIRCULATION, V112, P3408, DOI 10.1161/CIRCULATIONHA.105.564971 | - |
dc.description.citedreference | Nguyen MTA, 2005, J BIOL CHEM, V280, P35361, DOI 10.1074/jbc.M504611200 | - |
dc.description.citedreference | Tschope C, 2005, FASEB J, V19, P2057, DOI 10.1096/fj.05-4095fje | - |
dc.description.citedreference | Yoon YS, 2005, CIRCULATION, V111, P2073, DOI 10.1161/01.CIR.0000162472.52990.36 | - |
dc.description.citedreference | Tschope C, 2004, FASEB J, V18, P1967, DOI 10.1096/fj.04-1614fje | - |
dc.description.citedreference | Nian M, 2004, CIRC RES, V94, P1543, DOI 10.1161/01.RES.0000130526.20854.fa | - |
dc.description.citedreference | Tsutamoto T, 2004, EUR J HEART FAIL, V6, P173, DOI 10.1016/j.ejheart.2003.10.004 | - |
dc.description.citedreference | Hasselbaink DM, 2003, BIOCHEM J, V371, P753 | - |
dc.description.citedreference | Poirier P, 2001, DIABETES CARE, V24, P5 | - |
dc.description.citedreference | Adlard JW, 2000, ANTI-CANCER DRUG, V11, P787 | - |
dc.description.citedreference | JACOBSON JM, 2000, EXPERT OPIN PHARMACO, V1, P849 | - |
dc.description.citedreference | Raje N, 1999, NEW ENGL J MED, V341, P1606 | - |
dc.description.citedreference | Tschope C, 1999, IMMUNOPHARMACOLOGY, V44, P35 | - |
dc.description.citedreference | Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416 | - |
dc.description.citedreference | Rodrigues B, 1998, MOL CELL BIOCHEM, V180, P53 | - |
dc.description.citedreference | Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577 | - |
dc.description.citedreference | Yokoyama T, 1997, CIRCULATION, V95, P1247 | - |
dc.description.citedreference | MALKUSCH W, 1995, EXP LUNG RES, V21, P67 | - |
dc.description.citedreference | KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035 | - |
dc.description.citedreference | WEISS JL, 1976, J CLIN INVEST, V58, P751 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.